<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0263541" disease_type="Disease or Syndrome" abbrv="">Founder</z:e> mutations with a large impact in distinct populations have been described in <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In Denmark, the MLH1 c.1667+2_1667_+8TAAATCAdelinsATTT mutation accounts for 25 % of the MLH1 mutant families </plain></SENT>
<SENT sid="2" pm="."><plain>We used the national Danish <z:e sem="disease" ids="C1333990" disease_type="Neoplastic Process" abbrv="">hereditary nonpolyposis colorectal cancer</z:e> register to estimate the cumulative lifetime risks for <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e>-associated <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in 16 founder mutation families with comparison to 47 other MLH1 mutant families </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:e sem="disease" ids="C0263541" disease_type="Disease or Syndrome" abbrv="">founder</z:e> mutation conferred comparable risks for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (relative risks, RR, of 0.99 for males and 0.79 for females) and lower risks for extracolonic <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (RR of 0.69 for <z:e sem="disease" ids="C0476089" disease_type="Neoplastic Process" abbrv="">endometrial cancer</z:e> and 0.39 for <z:hpo ids='HP_0000001'>all</z:hpo> other extracolonic <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>) </plain></SENT>
<SENT sid="4" pm="."><plain>We also characterized expression of key Wnt-signaling proteins in <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> with the <z:e sem="disease" ids="C0263541" disease_type="Disease or Syndrome" abbrv="">founder</z:e> mutation </plain></SENT>
<SENT sid="5" pm="."><plain>Aberrant staining affected β-catenin in 59 %, E-cadherin in 68 %, TCF-4 in 94 % and Cyclin D1 in 68 % with extensive inter-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> variability despite the same underlying germline mutation </plain></SENT>
<SENT sid="6" pm="."><plain>In conclusion, the Danish MLH1 <z:e sem="disease" ids="C0263541" disease_type="Disease or Syndrome" abbrv="">founder</z:e> mutation that accounts for a significant proportion of <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> and is associated with a lower risk for extracolonic <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
</text></document>